Importantly, although clinical trials have shown mixed results, they suggest that n-3 supplementation may be most beneficial in early-stage AD or among individuals with specific genetic profiles, such as APOE4 non-carriers (Yassine et al., 2017). The gene discussed is APOE; the disease is Alzheimer disease.